

B<sup>1</sup> sub c1 10. (Amended) A method of identifying a compound that modulates anxiety, said method comprising:  
selecting, as a test compound, a compound that modulates the activity of PKCε,  
and  
administering said test compound to a test animal subject to anxiety to determine whether said anxiety is modulated.

B<sup>2</sup> sub c2 29. (Amended) The method of claim 10, wherein said compound selectively inhibits the activity of PKC epsilon and said anxiety is reduced.

Cancel claim 30. ✓

B<sup>3</sup> sub c3 31. (Amended) The method of claim 29, wherein said reduction of anxiety in a test animal is selected from the group consisting of: decreased locomotor activity, decreased time in open areas, decreased exploratory behavior, and increased basal level of a stress hormone.

32. (Reiterated) A method of identifying compounds that modulate anxiety, said method comprising:  
exposing a functional PKC epsilon to a test compound,  
determining whether the test compound modulates the activity of PKC epsilon, wherein test compounds that modulate the activity of PKC epsilon are identified as compounds for modulating anxiety.

33. (Reiterated) The method of claim 32, wherein said exposing is performed in a cell or cell lysate.

Cancel claim 34. ✓

B<sup>4</sup> sub c4 35. (Amended) A method of identifying compounds that modulate anxiety, said method comprising:

measuring the activity of PKC epsilon in the presence and absence of a test compound,  
determining whether the test compound modulates the activity of PKC epsilon,  
administering to an animal subject to anxiety a test compound that modulates the activity of PKC epsilon and  
determining whether the animal's anxiety is modulated, wherein test compounds that modulate the animal's anxiety are identified as compounds for modulating anxiety.

36. (Reiterated) The method of claim 35, wherein said measuring is performed in a cell or cell lysate.

37. (Reiterated) The method of claim 35, wherein said measuring is performed in an in vitro assay.

38. (Reiterated) The method of claim 35, wherein said administering occurs under conditions in which the animal, in the absence of the test compound, displays symptoms of anxiety.

39. (Reiterated) The method of claim 35, wherein said second determining step is performed after the animal is exposed to an anxiety-producing stimulus.

### REMARKS

#### **I. ENABLEMENT**

Claims 10 and 29-39 were rejected under 35 U.S.C. §112, first paragraph, because the Examiner maintains that the invention recites a method of identifying compounds that modulate anxiety, said method may have only one step comprising testing effect of the compounds on the activity of PKC-epsilon which would indicate that the compound has anxiety-modulating effects or said method comprises a step of first determining whether a compound modulates PKC-epsilon activity and then testing its anxiety modulatory